OmniAb (NASDAQ:OABIW – Get Free Report) is projected to post its results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $4.6930 million for the quarter.
OmniAb Stock Performance
OABIW opened at $0.08 on Wednesday. OmniAb has a 12 month low of $0.04 and a 12 month high of $0.29. The business has a 50-day moving average of $0.09 and a two-hundred day moving average of $0.09.
About OmniAb
OmniAb, Inc is a clinical?stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high?throughput screening and bioinformatics, OmniAb aims to streamline the development of next?generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single?cell screening capabilities.
Featured Articles
- Five stocks we like better than OmniAb
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
